Positron Emission Tomography in Transcranial Magnetic Stimulation Intervention for Treatment-resistant Depression
Launched by FIRST AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY · Sep 12, 2023
Trial Information
Current as of August 21, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This clinical trial is studying how visual perception is affected in people with treatment-resistant depression (TRD) and whether a specific treatment called high-frequency repetitive transcranial magnetic stimulation (rTMS) can help improve it. The researchers want to understand how certain areas of the brain, particularly the middle temporal visual area (MT), are involved in visual perception issues that some people with TRD experience. By comparing the visual perception abilities of those with TRD to healthy individuals, the study aims to uncover the potential effects of rTMS on visual perception and the underlying brain changes that happen during treatment.
To be eligible for this trial, participants must be between 18 and 45 years old, have not responded to at least two different antidepressant treatments, and have a certain level of depression based on a specific scoring system. Participants will undergo various tests, including brain scans and psychological assessments, before and after receiving the rTMS treatment. This will help researchers gather important data on how the treatment works and its effectiveness in improving visual perception. It's important to note that individuals with certain mental health conditions or medical issues, as well as those who are pregnant or breastfeeding, will not be able to participate.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Receive two or more adequate doses and courses of antidepressant drugs in different mechanisms that were not effective and had been stable for more than 6 weeks on antidepressant medication prior to enrollment, with non-responsiveness defined as a decrease in HAMD-24 score of \<50%.
- • 2. 24-item Hamilton Depression Scale (HAMD-24) ≥ 20.
- • 3. Normal or corrected to normal vision.
- • 4. Ability to complete spatial suppression psychophysical experiment.
- • 5. education background above the college degree.
- • 6. Age 18-45 years, regardless of gender.
- • 7. Right-handedness.
- • 8. Han Chinese.
- • 9. Signed a written informed consent, willing to participate in the study and be evaluated.
- Exclusion Criteria:
- • 1. Co-morbid other mental disorders, including: schizophrenia, mental retardation, substance dependence, etc.
- • 2. Patients with metal objects in the body or with other contraindications to PET-MRI scanning
- • 3. Patients with severe or unstable somatic diseases
- • 4. Women during pregnancy or lactation, and women of childbearing age with positive urine HCG test results during the screening period
- • 5. Benzodiazepines were taken during the experimental period
- • 6. Other conditions that, in the opinion of the investigator, exist that make participation in this clinical trial inappropriate.
About First Affiliated Hospital Of Zhejiang University
The First Affiliated Hospital of Zhejiang University is a leading medical institution located in Hangzhou, China, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a prominent sponsor of clinical trials, the hospital leverages its extensive network of specialists and state-of-the-art facilities to facilitate groundbreaking studies across various medical disciplines. With a focus on improving patient outcomes and contributing to global medical knowledge, the hospital actively engages in collaborative research initiatives, ensuring rigorous adherence to ethical standards and regulatory compliance. Its dedication to fostering a culture of scientific inquiry underscores its role as a pivotal player in the advancement of medical science and patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hangzhou, Zhejiang, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported